ArticleFrontiers in immunology2024
Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors.
Felix Scheuplein et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it